Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 1463947.
- Also identified by PMC identifier 1883704.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To examine the effects of taking drugs affecting bone metabolism on the risk of hip fracture in women aged over 50 years. Retrospective, population based, case-control study by questionnaire. 14 centres in six countries in southern Europe. 2086 women with hip fracture and 3532 control women matched for age. Number of drugs affecting bone metabolism taken and length taken for. Women taking drugs affecting bone metabolism had a significantly decreased risk of hip fracture. After adjustment for differences in other risk factors, the relative risk of hip fractures was 0.55 (95% confidence interval 0.31 to 0.85) in women taking oestrogens, 0.75 (0.60 to 0.94) in those taking calcium, and 0.69 (0.51 to 0.92) in those taking calcitonin. The fall in risk was not significant for anabolic steroids (0.6 (0.29 to 1.22)). Neither vitamin D nor fluorides were associated with a significant decrease in the risk of hip fracture. The effect on hip fracture risk increased significantly with increasing duration of exposure (risk ratio 0.8 (0.61 to 1.05) for less than median exposure v 0.66 (0.5 to 0.88) for greater than median exposure). Drugs were equally effective in older and younger women, with the exception of oestrogen. Oestrogen, calcium, and calcitonins significantly decrease the risk of hip fracture. Short term intervention late in the natural course of osteoporosis may have significant effects on the incidence of hip fracture.
Medical subject headings
- Bone and Bones
- Hip Fractures